Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 3
2015 1
2016 5
2017 2
2018 3
2019 2
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI. Patnaik A, et al. Among authors: cronier dm. Cancer Discov. 2016 Jul;6(7):740-53. doi: 10.1158/2159-8290.CD-16-0095. Epub 2016 May 23. Cancer Discov. 2016. PMID: 27217383 Free article.
Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.
Villalobos VM, Mo G, Agulnik M, Pollack SM, Rushing DA, Singh A, Van Tine BA, McNaughton R, Decker RL, Zhang W, Shahir A, Cronier DM. Villalobos VM, et al. Among authors: cronier dm. Cancer Med. 2020 Feb;9(3):882-893. doi: 10.1002/cam4.2728. Epub 2019 Dec 10. Cancer Med. 2020. PMID: 31821732 Free PMC article. Clinical Trial.
Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma.
Jones RL, Mo G, Baldwin JR, Peterson PM, Ilaria RL Jr, Conti I, Cronier DM, Tap WD. Jones RL, et al. Among authors: cronier dm. Cancer Chemother Pharmacol. 2019 Jan;83(1):191-199. doi: 10.1007/s00280-018-3723-4. Epub 2018 Nov 8. Cancer Chemother Pharmacol. 2019. PMID: 30406840 Free PMC article. Clinical Trial.
A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models.
Yin T, Lallena MJ, Kreklau EL, Fales KR, Carballares S, Torrres R, Wishart GN, Ajamie RT, Cronier DM, Iversen PW, Meier TI, Foreman RT, Zeckner D, Sissons SE, Halstead BW, Lin AB, Donoho GP, Qian Y, Li S, Wu S, Aggarwal A, Ye XS, Starling JJ, Gaynor RB, de Dios A, Du J. Yin T, et al. Among authors: cronier dm. Mol Cancer Ther. 2014 Jun;13(6):1442-56. doi: 10.1158/1535-7163.MCT-13-0849. Epub 2014 Mar 31. Mol Cancer Ther. 2014. PMID: 24688048 Free article.
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.
Raje NS, Moreau P, Terpos E, Benboubker L, Grząśko N, Holstein SA, Oriol A, Huang SY, Beksac M, Kuliczkowski K, Tai DF, Wooldridge JE, Conti I, Kaiser CJ, Nguyen TS, Cronier DM, Palumbo A. Raje NS, et al. Among authors: cronier dm. Br J Haematol. 2017 Mar;176(5):783-795. doi: 10.1111/bjh.14483. Epub 2016 Dec 22. Br J Haematol. 2017. PMID: 28005265 Clinical Trial.
Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.
Raje NS, Faber EA Jr, Richardson PG, Schiller G, Hohl RJ, Cohen AD, Forero A, Carpenter S, Nguyen TS, Conti I, Kaiser CJ, Cronier DM, Wooldridge JE, Anderson KC. Raje NS, et al. Among authors: cronier dm. Clin Cancer Res. 2016 Dec 1;22(23):5688-5695. doi: 10.1158/1078-0432.CCR-16-0201. Epub 2016 Jun 10. Clin Cancer Res. 2016. PMID: 27287072 Free article. Clinical Trial.
14 results